Anti-PACAP antibody
First Claim
Patent Images
1. An antibody that binds human pituitary adenylate cyclase-activating peptide comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3 and the LCVR comprises CDRs LCDR1, LCDR2, and LCDR3, wherein the amino acid sequence of HCDR1 is SEQ ID NO:
- 3, the amino acid sequence of HCDR2 is SEQ ID NO;
4, the amino acid sequence of HCDR3 is SEQ ID NO;
5, the amino acid sequence of LCDR1 is SEQ ID NO;
6, the amino acid sequence of LCDR2 is SEQ ID NO;
7, and the amino acid sequence of LCDR3 is SEQ ID NO;
8, and whereinHCDR2 comprises aspartic acid, alanine, glutamic acid or glutamine at residue 13 of SEQ ID NO;
4;
HCDR3 comprises asparagine or threonine at residue 8 of SEQ ID NO;
5;
LCDR1 comprises serine or tryptophan at residue 7 of SEQ ID NO;
6; and
LCDR2 comprises leucine or phenylalanine at residue 7 of SEQ ID NO;
7.
1 Assignment
0 Petitions
Accused Products
Abstract
Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
9 Citations
18 Claims
-
1. An antibody that binds human pituitary adenylate cyclase-activating peptide comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3 and the LCVR comprises CDRs LCDR1, LCDR2, and LCDR3, wherein the amino acid sequence of HCDR1 is SEQ ID NO:
- 3, the amino acid sequence of HCDR2 is SEQ ID NO;
4, the amino acid sequence of HCDR3 is SEQ ID NO;
5, the amino acid sequence of LCDR1 is SEQ ID NO;
6, the amino acid sequence of LCDR2 is SEQ ID NO;
7, and the amino acid sequence of LCDR3 is SEQ ID NO;
8, and whereinHCDR2 comprises aspartic acid, alanine, glutamic acid or glutamine at residue 13 of SEQ ID NO;
4;HCDR3 comprises asparagine or threonine at residue 8 of SEQ ID NO;
5;LCDR1 comprises serine or tryptophan at residue 7 of SEQ ID NO;
6; andLCDR2 comprises leucine or phenylalanine at residue 7 of SEQ ID NO;
7. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 16, 17, 18)
- 3, the amino acid sequence of HCDR2 is SEQ ID NO;
-
11. An antibody that binds human pituitary adenylate cyclase-activating peptide comprising a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is SEQ ID NO:
- 1 and the amino acid sequence of the LC is SEQ ID NO;
2, wherein HC comprises aspartic acid, alanine, glutamic acid or glutamine at residue 62 and asparagine or threonine at residue 104 of SEQ ID NO;
1 and wherein LC comprises serine or tryptophan at residue 30 and leucine or phenylalanine at residue 55 of SEQ ID NO;
2. - View Dependent Claims (12, 13, 14, 15)
- 1 and the amino acid sequence of the LC is SEQ ID NO;
Specification